1317.9000 -7.40 (-0.56%)
NSE Jun 23, 2025 15:31 PM
Volume: 843.9K
 

1317.90
-0.56%
ICICI Securities Limited
Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment charge of gNuvaring (INR 924mn), was ahead of our expectations
Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr
More from Dr. Reddy's Laboratories Ltd.
Recommended